Abstract
Peroxisome proliferator-activated receptors (PPARs) are members of the steroid hormone receptor superfamily, discovered in 1990. To date, three PPAR subtypes have been identified; PPARα, PPAR β/δ, and PPARγ. These receptors share a high degree of homology but differ in tissue distribution and ligand specificity. PPARs have been implicated in the etiology as well as treatment of several important diseases and pathological conditions such as diabetes, inflammation, senescence-related diseases, regulation of fertility, and various types of cancer. Consequently, significant efforts to discover novel PPAR roles and delineate molecular mechanisms involved in their activation and repression as well as develop safer and more effective PPAR modulators, as therapeutic agents to treat a myriad of diseases and conditions, are underway. This volume of Methods in Molecular Biology contains details of experimental protocols used in researching these receptors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Lalwani ND et al (1983) Detection of a nafenopin binding protein in rat liver cytosol associated with induction of peroxisome proliferation by hypolipidemic compounds. Biochem Biophys Res Commun 116:388–393
Lalwani ND et al (1987) Peroxisome proliferator-binding protein: Identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver. Proc Natl Acad Sci USA 84:5242–5246
Alvares K et al (1990) Identification of cytosolic peroxisome proliferator binding protein as a member of the heat shock protein HSP70 family. Proc Natl Acad Sci USA 87:5293–5297
Isseman I, Green S (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347:645–650
Gottlicher M et al (1992) Fatty acids activate chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc Natl Acad Sci USA 89:4653–4657
Schmidt A et al (1992) Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6:1634–1641
Dreyer C et al (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68:879–887
Berger J, Moller DF (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409–435
Sher T et al (1993) cDNA cloning, chromosomal mapping and functional characterization of human peroxisome proliferator activated receptor. Biochemistry 32:5598–5604
Yoshikawa T et al (1996) Assignment of the human nuclear hormone receptor, NUC1 (PPAR delta), to chromosome 6p21.1–p21.2. Genomics 35:637–638
Greene ME et al (1995) Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 4:281–299
Bugge A, Mandrup S (2010) Molecular mechanisms and genome-wide aspects of PPAR subtype transactivation. PPAR Res 2010:169506
Kliewer SA et al (1992) Convergence of 9-Cis retinoic acid and peroxisome proliferator signaling pathways through heterodimer formation of their receptors. Nature 358:771–774
Gearing KL et al (1993) Interaction of peroxisome-proliferator-activated receptor and retinoid x-receptor. Proc Natl Acad Sci USA 90:1440–1444
Ijpenberg A et al (1997) Polarity and specific sequence requirements of peroxisome proliferator-activated receptor heterodimer binding to DNA. A functional analysis of the malic enzyme PPAR response element. J Biol Chem 272:20108–20117
Nielsen R et al (2006) Peroxisome proliferator-activated receptor subtype-and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. Mol Cell Biol 26:5698–5714
Gulick T et al (1994) The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91:11012–11016
Wang YX et al (2003) Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 113:159–170
Mueller E et al (2002) Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor gamma isoforms. J Biol Chem 277:41925–41930
Oberkofler H et al (2002) Peroxisome proliferator activated receptor (PPAR) γ coactivator-1 recruitment regulates PPAR subtype specificity. J Biol Chem 277:16750–16757
Racke M, Drew P (2008) PPARs in neuroinflammation. PPAR Res 2008:638356
Calkin AC, Thomas MC (2008) PPAR agonists and cardiovascular disease in diabetes. PPAR Res 2008:245410
Duval C et al (2002) The role of PPARs in atherosclerosis. Trends Mol Med 8:422–430
Standiford T, Roman J (2007) PPARs in lung biology and disease. PPAR Res 2007:28765
Matthiessen MW et al (2005) Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 40:198–205
Pathak R et al (2007) Effect of peroxisome proliferator-activated receptor-alpha agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats. Fundam Clin Pharmacol 21:291–296
Peters JM et al (2008) Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease. Clin Sci (Lond) 115:107–127
Kim HS et al (2008) Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression. Biochem Biophys Res Commun 367:623–629
Masuda K et al (1995) Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38:24–30
Han SJ et al (2008) Rosiglitazone inhibits early stage of glucolipotoxicity-induced beta-cell apoptosis. Horm Res 70:165–173
Holloway AC et al (2008) Rosiglitazone prevents diabetes by increasing beta-cell mass in an animal model of type 2 diabetes characterized by reduced beta-cell mass at birth. Diabetes Obes Metab 10:763–771
Tanaka T et al (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci (USA) 100:15924–15929
Syversen U et al (2009) Different skeletal effects of the peroxisome proliferator activated receptor (PPAR) alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 9:10
Still K et al (2008) The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 83:285–292
Braissant O et al (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354–366
Wang YX et al (2004) Regulation of muscle fiber type and running endurance by PPARdelta. PLoS Biol 2:e294
de Lange P et al (2008) Peroxisome proliferator-activated receptor delta: a conserved director of lipid homeostasis through regulation of the oxidative capacity of muscle. PPAR Res 2008:172676
Narkar VA et al (2008) AMPK and PPARdelta agonists are exercise mimetics. Cell 134:405–415
Thevis M et al (2010) Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem 396:2479–2491
Youssef J, Badr M (2011) PPARs and cancer: challenges and opportunities. Br J Pharmacol 164:68–82
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Youssef, J., Badr, M.Z. (2013). PPARs: History and Advances. In: Badr, M., Youssef, J. (eds) Peroxisome Proliferator-Activated Receptors (PPARs). Methods in Molecular Biology, vol 952. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-155-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-62703-155-4_1
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-154-7
Online ISBN: 978-1-62703-155-4
eBook Packages: Springer Protocols